Government receives plea to cut 28% GST on aerated drinks
The meeting is already set to review a broader rate rationalisation framework, with officials indicating that certain slabs and cesses may be simplified or merged.Carbonated drinks fall under the so-called 'sin goods' category—alongside tobacco and pan masala—which invites the highest GST rate and a cess. Industry players have long argued that such classification is outdated, especially for low-sugar and fruit-based carbonated products.Recent court rulings have also put pressure on the current tax structure. The Gauhati High Court had ruled that certain fizzy fruit drinks, if primarily juice-based, should be taxed at 12% instead of 28%. However, this has not led to a broader reclassification.While some states may resist the change due to the revenue implications of scrapping the cess, the Centre is reportedly open to exploring alternatives as part of a wider reform to make the GST system more predictable and investment-friendly.Any revision in GST rates or cess removal would likely translate into lower prices for consumers and improved margins for beverage makers.- Ends
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
a few seconds ago
- India.com
India's Pharma Exports Have Shot Up By 92% In Last 6 Years: Minister
New Delhi: Various schemes being implemented by the Centre to realise the vision of Aatmanirbhar Bharat in the pharmaceutical sector have resulted in India's exports of drugs and pharmaceuticals increasing by 92 per cent, from Rs 1,28,028 crore in FY2018-19 to Rs 2,45,962 crore in FY2024-25, the Parliament was informed on Friday. The schemes include the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, the PLI Scheme for Bulk Drugs, Scheme for Promotion of Bulk Drug Parks, and Strengthening of Pharmaceutical Industry scheme, Minister of State for Chemicals and Fertilisers Anupriya Patel told the Lok Sabha in a written reply to a question. The PRIP scheme has been launched with an outlay of Rs 5,000 crore to transform India's Pharma MedTech sector from cost- to innovation-based growth by strengthening research and promoting industry-academia linkage for research and development in priority areas in drug discovery and development and medical devices. Under this scheme, seven Centres of Excellence (CoEs) have been set up, she said. The PLI Scheme for Pharmaceuticals aims to enhance India's manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector. The minister said that the scheme has enabled enhanced investment and production in eligible products. As of March 2025, the committed investment of Rs 17,275 crore targeted over the six-year period of the scheme stands substantially exceeded with a cumulative investment of Rs 37,306 crore made by the scheme's third year, and cumulative sales of approved products of Rs 2,66,528 crore have been made, including exports of Rs 1,70,807 crore. The PLI Scheme for Bulk Drugs, which has a total budgetary outlay of Rs 6,940 crore, aims to avoid disruption in the supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on a single source. As of March 2025, the committed investment of Rs 3,938.5 crore under projects approved under the scheme for investment over the six-year production period of the scheme stands substantially exceeded with a cumulative investment of Rs 4,570 crore made by the scheme's third year, she further stated. The minister also highlighted that the government launched the Pradhan Mantri Bhartiya Janaushadhi Pariyojana scheme to make quality generic medicines available at affordable prices to all. Under the scheme, dedicated outlets known as Jan Aushadhi Kendras (JAKs) are opened across the country to provide medicines at prices that are about 50 per cent to 80 per cent lower than those of leading branded medicines in the market. Till June 6, 2025, a total of 16,912 JAKs have been opened, and on average, about 10 to 12 lakh persons visit these Kendras daily and avail of quality medicines at affordable prices. As many as 2,110 medicines and 315 surgicals, medical consumables and devices are under the scheme product basket, covering all major therapeutic groups, such as cardiovascular, anti-cancer, anti-diabetic, anti-infectives, anti-allergic and gastro-intestinal medicines and nutraceuticals. As a result of the scheme, in the last 11 years, estimated savings of about Rs 38,000 crore have accrued to citizens in comparison to the prices of branded medicines. Further, the scheme has provided self-employment to over 16,000 persons, including over 6,800 women entrepreneurs, the minister added.
New Indian Express
a few seconds ago
- New Indian Express
32-hr debate on Operation Sindoor kicks off from Monday
NEW DELHI: As the stand-off between Centre and the Opposition continued on the fifth day of the Monsoon session of Parliament, Lok Sabha Speaker Om Birla on Friday convened an all-party meeting where Opposition parties agreed to the agenda of taking up a special discussion on the Pahalgam terror attack and Operation Sindoor on Monday in Lok Sabha and the next day in Rajya Sabha, brightening the prospect of normalcy in both Houses. Briefing the media, Union Parliamentary Affairs Minister Kiren Rijiju said the decision to start a special discussion on the 'Terrorist attack in Pahalgam and in response to that Operation Sindoor carried out by the Indian Armed Forces' was agreed to at a meeting of leaders of different parties chaired by Speaker Om Birla. Defence Minister Rajnath Singh, Home Minister Amit Shah and External Affairs Minister S Jaishankar are expected to speak in the Lok Sabha amid indications that Prime Minister Modi may use the much-anticipated debate to turn up the heat on the Opposition, which looks to corner the government over alleged intelligence failures and US President Donald Trump's claims of mediating a 'ceasefire' between India and Pakistan.
News18
8 minutes ago
- News18
Hyundai India Gets Rs 517.34 Cr Tax With Penalty Demand From GST Authority, Here's Why
Last Updated: The company said there is no impact on its financial, operational or other activities due to the order and is reviewing the order and will exercise the right to file an appeal. Hyundai Motor India Ltd on Tuesday said it has received a demand of Rs 517.34 crore from tax authorities, along with penalty, for alleged short payment of GST compensation cess on its certain SUV models. The company has received an order from Commissioner (Appeals), CGST Dept, Tamil Nadu, confirming GST compensation cess demand of Rs 258.67 crore, along with penalty of Rs 258.67 crore, on the allegation of short payment of GST compensation cess on certain SUV models for the period September 2017 – March 2020, Hyundai Motor India Ltd said in a regulatory filing. Reacting to the demand, a company spokesperson said, 'HMIL is of the view that the amendment and the clarifications given by the Central Board of Indirect Tax and Customs (CBIC) to resolve the issue faced by the industry on this matter are in favour of the company. We are in the process of reviewing the order and will exercise the right to seek a legal remedy through an appropriate forum." The company asserted that there is no impact on its financial, operational or other activities due to the order and is reviewing the order and will exercise the right to file an appeal. . view comments First Published: July 26, 2025, 08:17 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
